Jiangsu Nhwa Pharmaceutical Co., Ltd. is a pharmaceutical company based in China specialized in manufacturing APIs and dosages. With a medium risk assessment score of 29.4, the company focuses on producing high-quality drugs while prioritizing ESG factors.